Publication | Closed Access

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications

VaccinologyVaccinationCross-protectionAdult SubjectsVaccine DevelopmentPost-influenza ComplicationsImmunologyImmunodominanceHumoral ImmunityVaccine EfficacyInfluenza VaccineFlu VaccinationMedicineVaccine ResearchInfluenza Vaccines